AlphaMadera's AlphaVal page computes Inhibrx Biosciences, Inc.'s fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag INBX as undervalued, fairly valued, or overvalued.

What is Inhibrx Biosciences, Inc.'s fair value?

Fair value for INBX is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value INBX?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from INBX's most recent reported fundamentals.

INBX - Inhibrx Biosciences, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $325.00 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

AlphaVal Unavailable

AlphaVal: INBX intrinsic value ($1,371) is 13x the stock price ($104.27). Likely stale financials (post-split price with pre-split EPS), ADR currency mismatch, or bad data.